Results for tag: "Reslizumab"

Reslizumab is a humanized monoclonal antibody used to treat severe asthma in adults and children aged 12 years and older. It is a type of respiratory drug that works by targeting and blocking the action of interleukin-5 (IL-5), a protein that plays a role in the development of eosinophilic inflammation. This inflammation is associated with asthma symptoms such as wheezing, coughing, and difficulty breathing. Reslizumab is administered as an intravenous infusion every four weeks. Reslizumab is approved for use in the United States, Europe, and other countries. It is marketed by Teva Pharmaceuticals, a global pharmaceutical company, under the brand name Cinqair. Other companies involved in the market include AstraZeneca, GlaxoSmithKline, and Sanofi. Show Less Read more